Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.

Broncus Technologies is a medical technology company focused on developing and commercializing innovative solutions for lung diseases. With LungPoint™, physicians plan bronchoscopic procedures and navigate to locations in the lungs accurately and quickly. Its line of Yield™ catheters are used to obtain tissue samples and detect blood vessels. Its patented treatment method, Airway Bypass using Exhale® Drug-Eluting Stents, is being investigated to determine if it can provide the first minimally-invasive treatment option for homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients.

Broncus Technologies is a medical technology company focused on developing minimally-invasive medical devices for emphysema and other lung diseases. Broncus is investigating the Exhale emphysema product line to perform our patented treatment method called Airway Bypass. Airway Bypass could be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, which constitutes the majority of the emphysema patient population. Broncus is currently enrolling patients worldwide in our pivotal EASE Trial investigating a treatment of severe homogeneous emphysema. Broncus is located in Mountain View, CA (San Francisco Bay area). Broncus International is located in Nyon, Switzerland.

EKOS Corporation pioneered the development and the clinical application of ultrasound accelerated thrombolysis, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions around the world use the EKOS EkoSonic Endovascular System to provide faster, safer and more complete dissolution of thrombus.

Part of Medtronic Plc, Covidien Pte Ltd. is a Singaporean company located in Singapore that manufactures and supplies medical equipment.

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

Nanjing Anji Biotechnology Co., Ltd., established on 2012-04-12, Business scope includes licensed projects:Drug retail;Veterinary drug business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Portaero, Inc develops device used to treat chronic obstructive pulmonary diseases. The company was formerly known as Respira Inc. The company was incorporated in 2007 and is based in Cupertino, California.

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. The company's lead product, the PLAC Test, measures Lp-PLA2 (lipoprotein-associated phospholipase A2) a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis, that cause the majority of cardiovascular events. The PLAC Test is the only blood test cleared by the FDA as an aid in assessing risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.

Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. It engages in the manufacture of new medicines and medical substances as well as the sale of healthy food. It operates through the Natural and Bio Substance business divisions. The company was founded by Sun-Young Kim on November 21, 1996 and is headquartered in Seoul, South Korea.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

HyperBranch Medical Technology, Inc., a medical device company, develops and markets products primarily for the traumatic or surgically induced wound market. It offers OcuSeal, a liquid ocular bandage for direct application on the surface of the eye to form an ocular bandage, thereby covering an opening in the eye and providing an immediate protective barrier; and Adherus Dural Sealant, which is used as an aid in dural repair in cranial and spinal surgeries, such as the treatment of intracranial aneurysms, tumors, and spinal disc disease. The company also provides Adherus Hernia Mesh Fixation, a device used as a replacement for tacks, staples, sutures, and 'O' rings in hernia repair procedur...

Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

Axon Therapies developed the SAVM procedure. Their novel approach to modulating the body’s sympathetic nervous system to restore balance in the circulatory system.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Boston Scientific Scimed, Inc. develops, manufactures, and markets medical devices used principally to treat cardiovascular disease.